首页> 外文期刊>JAMA: the Journal of the American Medical Association >Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial.
【24h】

Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial.

机译:西地那非治疗与抗抑郁药有关的性功能障碍:一项随机对照试验。

获取原文
获取原文并翻译 | 示例
       

摘要

CONTEXT: Sexual dysfunction is a common adverse effect of antidepressants that frequently results in treatment noncompliance. OBJECTIVE: To assess the efficacy of sildenafil citrate in men with sexual dysfunction associated with the use of selective and nonselective serotonin reuptake inhibitor (SRI) antidepressants. DESIGN, SETTING, AND PATIENTS: Prospective, parallel-group, randomized, double-blind, placebo-controlled trial conducted between November 1, 2000, and January 1, 2001, at 3 US university medical centers among 90 male outpatients (mean [SD] age, 45 [8] years) with major depression in remission and sexual dysfunction associated with SRI antidepressant treatment. INTERVENTION: Patients were randomly assigned to take sildenafil (n = 45) or placebo (n = 45) at a flexible dose starting at 50 mg and adjustable to 100 mg before sexual activity for 6 weeks. MAIN OUTCOME MEASURES: The primary outcome measure was score on the Clinical Global Impression-Sexual Function (CGI-SF); secondary measures were scores on the International Index of Erectile Function, Arizona Sexual Experience Scale, Massachusetts General Hospital-Sexual Functioning Questionnaire, and Hamilton Rating Scale for Depression (HAM-D). RESULTS: Among the 90 randomized patients, 93% (83/89) of patients treated per protocol took at least 1 dose of study drug and 85% (76/89) completed week 6 end-point assessments with last observation carried forward analyses. At a CGI-SF score of 2 or lower, 54.5% (24/44) of sildenafil compared with 4.4% (2/45) of placebo patients were much or very much improved (P<.001). Erectile function, arousal, ejaculation, orgasm, and overall satisfaction domain measures improved significantly in sildenafil compared with placebo patients. Mean depression scores remained consistent with remission (HAM-D score < or =10) in both groups for the study duration. CONCLUSION: In our study, sildenafil effectively improved erectile function and other aspects of sexual function in men with sexual dysfunction associated with the use of SRI antidepressants. These improvements may allow patients to maintain adherence with effective antidepressant treatment.
机译:背景:性功能障碍是抗抑郁药的常见不良反应,常常导致治疗不依从。目的:评估枸of酸西地那非对与使用选择性和非选择性5-羟色胺再摄取抑制剂(SRI)抗抑郁药有关的性功能障碍男性的疗效。设计,地点和患者:2000年11月1日至2001年1月1日在美国3个大学医疗中心对90名男性门诊患者进行的前瞻性,平行分组,随机,双盲,安慰剂对照试验(平均[SD年龄[45 [8]岁],伴有SRI抗抑郁药治疗的缓解和性功能减退严重抑郁。干预:患者被随机分配服用西地那非(n = 45)或安慰剂(n = 45),剂量为50 mg,可调整至100 mg,然后进行性活动,持续6周。主要观察指标:主要观察指标是临床总体印象-性功能(CGI-SF)评分;次要措施是国际勃起功能指数,亚利桑那州性经验量表,马萨诸塞州综合医院性功能问卷和汉密尔顿抑郁量表(HAM-D)。结果:在这90名随机分组的患者中,按方案治疗的患者中有93%(83/89)至少服用了1剂研究药物,而在第6周完成的终点评估中有85%(76/89)进行了最后观察,并进行了分析。在CGI-SF得分为2或更低时,西地那非的54.5%(24/44)与安慰剂患者的4.4%(2/45)相比有很大或非常多的改善(P <.001)。与安慰剂患者相比,西地那非的勃起功能,唤醒,射精,性高潮和总体满意度指标明显改善。在研究期间,两组的平均抑郁评分均与缓解率保持一致(HAM-D评分<或= 10)。结论:在我们的研究中,西地那非有效改善了与使用SRI抗抑郁药有关的性功能障碍的男性的勃起功能和其他性功能方面。这些改善可以使患者保持有效的抗抑郁治疗依从性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号